Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
出版年份 2018 全文链接
标题
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
作者
关键词
-
出版物
Frontiers in Oncology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-03-28
DOI
10.3389/fonc.2018.00086
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients
- (2017) Yoshihiro Ishida et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
- (2017) Joseph P. Antonios et al. NEURO-ONCOLOGY
- Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
- (2017) Kenji Chamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
- (2016) J. Chesney et al. ANNALS OF ONCOLOGY
- Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
- (2016) S Diem et al. BRITISH JOURNAL OF CANCER
- A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
- (2016) Young Kwang Chae et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
- (2016) S. J. Blake et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
- (2016) Omar Abdel-Rahman et al. Immunotherapy
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab
- (2016) Y. Nonomura et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Upregulation of granzyme B and interferon-γ mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: a case report
- (2016) H. Anegawa et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
- (2016) X. Xiao et al. Cancer Discovery
- Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
- (2016) Pei-Yu Huang et al. Oncotarget
- TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection
- (2016) Glen M. Chew et al. PLoS Pathogens
- Tolerogenic IDO+ Dendritic Cells Are Induced by PD-1-Expressing Mast Cells
- (2016) Cecilia Pessoa Rodrigues et al. Frontiers in Immunology
- Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
- (2016) Yumi Nonomura et al. OncoImmunology
- Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma
- (2016) Yuki Honda et al. OncoImmunology
- Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma
- (2015) A. Otsuka et al. CLINICAL CANCER RESEARCH
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- From mice to humans: developments in cancer immunoediting
- (2015) Michele W.L. Teng et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Hedgehog signaling in basal cell carcinoma
- (2015) Atsushi Otsuka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma
- (2015) Y. Kato et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer
- (2015) Yaxiong Zhang et al. MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity
- (2015) Tong Seng Lim et al. OncoImmunology
- Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
- (2014) D. Gardner et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
- (2014) Jin Won Kim et al. Gastric Cancer
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
- (2014) J. L. Lines et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- T cell responses: naïve to memory and everything in between
- (2013) Nathan D. Pennock et al. ADVANCES IN PHYSIOLOGY EDUCATION
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
- (2013) D V Chan et al. GENES AND IMMUNITY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
- (2012) Sandra Salvi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- PD-1 is a novel regulator of human B-cell activation
- (2012) Marie-Laure Thibult et al. INTERNATIONAL IMMUNOLOGY
- Viral acute lower respiratory infections impair CD8+ T cells through PD-1
- (2012) John J. Erickson et al. JOURNAL OF CLINICAL INVESTIGATION
- Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
- (2012) Hiroaki Saito et al. JOURNAL OF SURGICAL ONCOLOGY
- The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood
- (2012) Peter T Sage et al. NATURE IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes
- (2011) Maxime Chapon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- PD-1 on Immature and PD-1 Ligands on Migratory Human Langerhans Cells Regulate Antigen-Presenting Cell Activity
- (2010) Victor Peña-Cruz et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model
- (2010) Maria R. Sorensen et al. VACCINE
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
- (2009) Nobuhiro Nakamoto et al. PLoS Pathogens
- Phenotype and function of human T lymphocyte subsets: Consensus and issues
- (2008) Victor Appay et al. CYTOMETRY PART A
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started